Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
A Phase II Single-arm, Open-label Study of Atezolizumab and Derazantinib for Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A PHASE2 clinical study on Intrahepatic Cholangiocarcinoma, this trial is ongoing. The trial is conducted by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and has accumulated 11 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Oct 2022 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Oct 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Saarow, Germany , Berlin, Germany , Bonn, Germany , Cologne, Germany , Esslingen am Neckar, Germany , Frankfurt, Germany , Hanover, Germany , Krefeld, Germany , Leipzig, Germany , Mainz, Germany and 5 more locations